CG Oncology, Inc. $CGON Shares Bought by EcoR1 Capital LLC

EcoR1 Capital LLC lifted its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 3.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,102,000 shares of the company’s stock after buying an additional 37,200 shares during the period. CG Oncology makes up about 3.2% of EcoR1 Capital LLC’s investment portfolio, making the stock its 8th largest holding. EcoR1 Capital LLC’s holdings in CG Oncology were worth $74,583,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. NFSG Corp acquired a new stake in CG Oncology in the 1st quarter valued at approximately $34,000. Whittier Trust Co. of Nevada Inc. bought a new position in shares of CG Oncology in the fourth quarter worth $27,000. Comerica Bank increased its holdings in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the period. Fifth Third Bancorp bought a new stake in shares of CG Oncology during the first quarter valued at about $74,000. Finally, KBC Group NV acquired a new stake in CG Oncology in the first quarter worth about $78,000. 26.56% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CGON has been the topic of several research analyst reports. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Truist Financial reiterated a “buy” rating and issued a $82.00 price target (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of CG Oncology in a report on Monday, May 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research note on Friday, July 17th. Finally, Wolfe Research initiated coverage on CG Oncology in a research report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CG Oncology has an average rating of “Moderate Buy” and a consensus target price of $81.73.

Insider Activity at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total transaction of $350,000.00. Following the sale, the director directly owned 5,000 shares of the company’s stock, valued at approximately $350,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian Guan-Chyun Liu acquired 371,085 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were purchased at an average cost of $66.87 per share, with a total value of $24,814,453.95. Following the acquisition, the director owned 1,886,236 shares of the company’s stock, valued at approximately $126,132,601.32. This represents a 24.49% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 37,129 shares of company stock valued at $2,663,817 in the last ninety days. Insiders own 4.80% of the company’s stock.

CG Oncology Price Performance

Shares of CGON stock opened at $73.52 on Tuesday. The stock’s fifty day simple moving average is $65.48 and its 200 day simple moving average is $62.71. CG Oncology, Inc. has a one year low of $23.65 and a one year high of $77.00. The firm has a market cap of $6.48 billion, a price-to-earnings ratio of -31.55 and a beta of 0.22.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The business had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. On average, research analysts anticipate that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.